乙酰胆碱酯酶抑制剂在阿尔茨海默病治疗中的研究进展

lzheimer's disease (AD), which is characterized by progressive loss of memory and impairment in cognition, is becoming a serious threat to life expectancy for elderly people. Current clinical therapy for AD patients is mainly palliative treatment targeting acetylcholinesterase (AChE). Recently AChE, particularly the peripheral anionic sites (PAS), was indicated to be involved in Aβ peptide aggregation-promoting action. Bivalent AChE inhibitors simultaneously blocking both the catalytic and PAS might not only alleviate the cognitive deficit of AD patients by elevating ACh levels, but also act as disease-modifying agents delaying amyloid plaque formation.